NCT01272986View on ClinicalTrials.gov

Trial of Screening for ALOA-IgG AtheroAbzyme Test

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Myocardial IschemiaAcute Coronary Syndrome
Interventions
DEVICE

ALOA IgG-Elisa

measurement of IgG Level in blood

DEVICE

ALOA IgG-AtheroAbzyme

measurement of IgG in blood

Trial Locations (1)

Unknown

Bahman Hospital, Beirut

Sponsors
All Listed Sponsors
lead

Omicron Pharmaceuticals

INDUSTRY

NCT01272986 - Trial of Screening for ALOA-IgG AtheroAbzyme Test | Biotech Hunter | Biotech Hunter